Desmoid Tumors Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | AFT Pharma, Timber Pharma, SpringWorks Therapeutics, Iterion Therapeutics

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Desmoid Tumors pipeline constitutes 4+ key companies continuously working towards developing 4+ Desmoid Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Desmoid Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Desmoid Tumors Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Desmoid Tumors Market.

Some of the key takeaways from the Desmoid Tumors Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Desmoid Tumors treatment therapies with a considerable amount of success over the years. Desmoid Tumors Key players such as - SpringWorks Therapeutics, Immunome/Ayala Pharmaceuticals, Iterion Therapeutics, Eisai and PRISM BioLab, MedPacto, Inc., Pfizer, Novartis, Ayala Pharmaceuticals, Iterion Therapeutics, Aadi Bioscience, Inc., INSYS Therapeutics Inc, Recursion Pharmaceuticals Inc, and others, are developing therapies for the Desmoid Tumors treatment

*
Desmoid Tumors Emerging therapies such as - OGSIVEO (nirogacestat), AL102, Tegavivint (BC2059), E7386, Vactosertib, Sirolimus, Imatinib, AL102, Tegavivint, Nab-Rapamycin, Fentanyl sublingual spray, REC-4881, and others are expected to have a significant impact on the Desmoid Tumors market in the coming years.

*
In March 2024, Immunome, Inc. (Nasdaq: IMNM), a biotechnology firm dedicated to creating innovative targeted cancer therapies, announced the successful acquisition of AL102 and the related drug candidate AL101 from Ayala Pharmaceuticals, Inc.

*
In June 2025, SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company specializing in rare diseases and cancer, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of nirogacestat. This oral gamma secretase inhibitor is proposed as a monotherapy for adults with progressing desmoid tumors in need of systemic therapy. The recommendation now moves to the European Commission (EC), which is expected to issue a final decision on the approval during the third quarter of 2025.

Get a Free Sample PDF Report to know more about Desmoid Tumors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/desmoid-tumors-pipeline-insight [https://www.delveinsight.com/report-store/desmoid-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Desmoid Tumors Overview

Desmoid tumors, also known as aggressive fibromatosis, are rare, non-metastatic but locally invasive tumors that arise from the connective tissue, which includes tendons and ligaments. Although they do not spread to distant organs, desmoid tumors can be very aggressive locally and can recur after surgical removal.

Emerging Desmoid Tumors Drugs Under Different Phases of Clinical Development Include:

*
OGSIVEO (nirogacestat): SpringWorks Therapeutics

*
AL102: Immunome/Ayala Pharmaceuticals

*
Tegavivint (BC2059): Iterion Therapeutics

*
E7386: Eisai and PRISM BioLab

*
Vactosertib: MedPacto, Inc.

*
AL102: Ayala Pharmaceuticals

*
Tegavivint: Iterion Therapeutics

*
Sirolimus: Pfizer

*
Imatinib: Novartis

*
Nab-Rapamycin: Aadi Bioscience, Inc.

*
Fentanyl sublingual spray: INSYS Therapeutics Inc

*
REC-4881: Recursion Pharmaceuticals Inc

Route of Administration

Desmoid Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Intravenous

*
Subcutaneous

*
Parenteral

*
Topical

Molecule Type

Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

Desmoid Tumors Pipeline Therapeutics Assessment

*
Desmoid Tumors Assessment by Product Type

*
Desmoid Tumors By Stage and Product Type

*
Desmoid Tumors Assessment by Route of Administration

*
Desmoid Tumors By Stage and Route of Administration

*
Desmoid Tumors Assessment by Molecule Type

*
Desmoid Tumors by Stage and Molecule Type

DelveInsight's Desmoid Tumors Report covers around 4+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Desmoid Tumors product details are provided in the report. Download the Desmoid Tumors pipeline report to learn more about the emerging Desmoid Tumors therapies [https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Desmoid Tumors Therapeutics Market include:

Key companies developing therapies for Desmoid Tumors treatment are - SpringWorks Therapeutics, Iterion Therapeutics, Cellestia Biotech, BioSpecifics Technologies Corp., 180 Life Sciences, AFT Pharma, Timber Pharmaceuticals, MedPacto, Intas Pharmaceuticals, Jina pharmaceuticals, and others

Desmoid Tumors Pipeline Analysis:

The Desmoid Tumors pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Desmoid Tumors with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Desmoid Tumors Treatment.

*
Desmoid Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Desmoid Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Desmoid Tumors market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Desmoid Tumors drugs and therapies [https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Desmoid Tumors Pipeline Market Drivers

*
No licensed therapy for Desmoid Tumor, which presents an opportunity for pharmaceutical companies to enter the market

*
Market growth of Desmoid Tumors will be boosted by increased R&D and the anticipated introduction of new therapies

Desmoid Tumors Pipeline Market Barriers

*
There are challenges in conducting rare cancer clinical trials due to issues surrounding clinical trial design, patient recruitment, and analysis

*
Lack of approved therapies poses a significant burden on Desmoid Tumors patients

*
Owing of its rarity, Desmoid Tumors poses research obstacles, and only a few attempts have been made to develop medications for the condition

Scope of Desmoid Tumors Pipeline Drug Insight

*
Coverage: Global

*
Key Desmoid Tumors Companies: SpringWorks Therapeutics, Immunome/Ayala Pharmaceuticals, Iterion Therapeutics, Eisai and PRISM BioLab, MedPacto, Inc., Pfizer, Novartis, Ayala Pharmaceuticals, Iterion Therapeutics, Aadi Bioscience, Inc., INSYS Therapeutics Inc, Recursion Pharmaceuticals Inc, and others

*
Key Desmoid Tumors Therapies: OGSIVEO (nirogacestat), AL102, Tegavivint (BC2059), E7386, Vactosertib, Sirolimus, Imatinib, AL102, Tegavivint, Nab-Rapamycin, Fentanyl sublingual spray, REC-4881, and others

*
Desmoid Tumors Therapeutic Assessment: Desmoid Tumors current marketed and Desmoid Tumors emerging therapies

*
Desmoid Tumors Market Dynamics: Desmoid Tumors market drivers and Desmoid Tumors market barriers

Request for Sample PDF Report for Desmoid Tumors Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Desmoid Tumors Report Introduction

2

Desmoid Tumors Executive Summary

3

Desmoid Tumors Overview

4

Desmoid Tumors- Analytical Perspective In-depth Commercial Assessment

5

Desmoid Tumors Pipeline Therapeutics

6

Desmoid Tumors Late Stage Products (Phase II/III)

7

Desmoid Tumors Mid Stage Products (Phase II)

8

Desmoid Tumors Early Stage Products (Phase I)

9

Desmoid Tumors Preclinical Stage Products

10

Desmoid Tumors Therapeutics Assessment

11

Desmoid Tumors Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Desmoid Tumors Key Companies

14

Desmoid Tumors Key Products

15

Desmoid Tumors Unmet Needs

16

Desmoid Tumors Market Drivers and Barriers

17

Desmoid Tumors Future Perspectives and Conclusion

18

Desmoid Tumors Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=desmoid-tumors-pipeline-2025-latest-fda-approvals-clinical-trials-and-emerging-therapies-assessment-by-delveinsight-aft-pharma-timber-pharma-springworks-therapeutics-iterion-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.